Skip to main content

Bill Russell Archives

Study sheds light on drug’s impact on diabetes progression

Mar. 23, 2023—A Vanderbilt study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.

Read more


Study drug delays type 1 diabetes in high risk children and adults

Jun. 9, 2019—Drug delays onset of type 1 diabetes by two years

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more